Your search history is turned on.
Date: March 14, 2013 Jurisdictions: All jurisdictions
Akela Pharma, Inc. Announces Completion of Asset Foreclosure on Formulation Technologies, LLC Akela Pharma, Inc. Announces Completion of Asset Foreclosure on Formulation Technologies, LLC VANCOUVER, March 14, 2013 /CNW Telbec/ - Akela Pharma, Inc. (the "Corporation") has announced that the asset foreclosure on its wholly owned subsidiary, Formulation Technologies, LLC d/b/a PharmaForm, was completed ...
Date: March 11, 2013 Jurisdictions: All jurisdictions
Rudy Emmelot resigns from Akela Pharma, Inc. Rudy Emmelot resigns from Akela Pharma, Inc. VANCOUVER, March 11, 2013 /CNW Telbec/ - Rudy Emmelot has announced his resignation as President, CEO and Member of the Board of Directors of Akela Pharma, Inc. SOURCE: AKELA PHARMA INC. %SEDAR: 00003466E For further information: Rudy Emmelot 512-468-0008 512-834-0449 CO: AKELA PHARMA INC. CNW ...
Date: February 22, 2013 Jurisdictions: All jurisdictions
Akela Pharma, Inc. Announces Notice of Asset Foreclosure on Formulation Technologies, LLC Akela Pharma, Inc. Announces Notice of Asset Foreclosure on Formulation Technologies, LLC VANCOUVER, Feb. 22, 2013 /CNW Telbec/ - Akela Pharma, Inc. (the "Corporation") has announced that its wholly owned subsidiary, Formulation Technologies, LLC received a notice of default and that on February 13, 2013, the Su...
Date: December 7, 2012 Jurisdictions: All jurisdictions
Akela Pharma, Inc. delists from the Toronto Stock Exchange Akela Pharma, Inc. delists from the Toronto Stock Exchange VANCOUVER, Dec. 7, 2012 /CNW Telbec/ - Akela Pharma, Inc. (TSX: AKL) (the "Corporation") has announced that voluntary delisting of the Coproration's securities from the Toronto Stock Exchange (TSX) will occur at the close of trading on December 7, 2012. The decision to voluntarily ...
Date: November 30, 2012 Jurisdictions: Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, Saskatchewan
Financial Statements of AKELA PHARMA, INC. ANNOUNCES VOLUNTARY DELISTING FROM THE TORONTO STOCK EXCHANGE Vancouver, BC; November 29, 2012 Akela Pharma, Inc. (TSX:AKL) advises that it has applied for the voluntary delisting of its securities from the Toronto Stock Exchange (TSX). Subject to confirmation from the TSX, it is ex...
Date: September 21, 2012 Jurisdictions: All jurisdictions
Akela Pharma, Inc. announces Board of Director transition Akela Pharma, Inc. announces Board of Director transition AUSTIN, TX, Sept. 21, 2012 /CNW Telbec/ - Akela Pharma, Inc. (TSX: AKL) today announced that Mr. Beng Lai is stepping down as a member of the Board of Directors of Akela Pharma, Inc. in order that he can devote more time to his principal business role as the President of a registered se...
Date: August 14, 2012 Jurisdictions: All jurisdictions
Akela Pharma reports results for the three and six months ended June 30, 2012 Akela Pharma reports results for the three and six months ended June 30, 2012 AUSTIN, TX, Aug. 14, 2012 /CNW Telbec/ - Akela Pharma, Inc. ("Akela"), (TSX: AKL), an industry leader in providing contract drug formulation development as well as pharmaceutical clinical and commercial manufacturing, today announced its financial...
Date: August 14, 2012 Jurisdictions: Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, Saskatchewan
AKELA PHARMA INC. Condensed Interim Consolidated Financial Statements As at June 30, 2012 and for the three-month and six month periods ended June 30, 2012 and 2011 (in United States dollars) (unaudited) UNAUDITED INTERIM FINANCIAL STATEMENTS In ac...
MANAGEMENTS DISCUSSION AND ANALYSIS OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS PAGE 1 Akela Pharma, Inc. MANAGEMENTS DISCUSSION AND ANALYSIS OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following Managements Discussion and Analysis of Financial Condition and Result...
FORM 52-109F2 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I Berenice Brownlee, Chief Financial Officer, Akela Pharma, Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Akela Pharma, Inc. for the interim period ended June 30, 2012. ...